Analyst firms · H.C. Wainwright · XERS
H.C. Wainwright XERS price target and rating history
Xeris Biopharma Holdings Inc. (XERS) · Health Care
H.C. Wainwright rates Xeris Biopharma Holdings Inc. (XERS) Buy with a $10 price target, as of its latest action on Aug 12, 2025. It has published 3 rating actions on XERS since October 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Buy
- Price target
- $10
- Median target, all firms
- Too few
- Actions on XERS
- 3
H.C. Wainwright price target on XERS
Every H.C. Wainwright rating on XERS
- Aug 12, 2025
- Dec 31, 2021
- Oct 29, 2021
Questions about H.C. Wainwright and XERS
- What is H.C. Wainwright's price target for XERS?
- H.C. Wainwright's latest stated price target for Xeris Biopharma Holdings Inc. (XERS) is $10, from its action on Aug 12, 2025.
- What is H.C. Wainwright's rating on XERS?
- H.C. Wainwright rates XERS Buy, a bullish rating, as of Aug 12, 2025.
- When did H.C. Wainwright last change its view on XERS?
- On Aug 12, 2025, H.C. Wainwright resumes coverage at Buy, price target $10.
More XERS rating histories
All H.C. Wainwright ratingsXERS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.